Results 131 to 140 of about 116,714 (299)
Suitability of the WHO 25 x 25 chronic disease targets and indicators for Australia [PDF]
The World Health Organization’s (WHO) Global Action Plan for the Prevention and Control of NCDs 2013‐2020 aims to reduce the burden of non‐communicable diseases by 2025, through action on nine targets measured by 25 indicators of performance.
Jason Leung, Penny Tolhurst
core
The Voice of Cantú: Lower Voice Pitch Is a New Phenotypic Feature of Cantú Syndrome
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Cantú syndrome (CS) is a rare genetic condition caused by pathogenic variants in either ABCC9 or KCNJ8, leading to gain‐of‐function of KATP‐channels. The main clinical features are hypertrichosis and cardiovascular abnormalities. This study investigates the voice characteristics in individuals with CS, an aspect that has received little ...
Lotte Kleinendorst +4 more
wiley +1 more source
Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman +9 more
wiley +1 more source
, 2023 Aim: The present study aimed to determine if foreign-born women from different countries of birth have a greater risk of GDM compared to Swedish-born women and to what extent income might mediate this relationship. Methods: This cross-sectional type study included 835279 women, of which 151,642 were foreign-born and 683637 were Swedish-born women who ...
Sharmin, Shayla, Usama, Muhammad
openaire +1 more source
Annals of Neurology, EarlyView.Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono +3 more
wiley +1 more source
Annals of Neurology, EarlyView.Objective Antiseizure medication (ASM) use during pregnancy has increased over the past decade. However, evidence linking prenatal ASM exposure to neurodevelopmental disorders (NDDs) in offspring remains inconsistent. This study evaluated whether prenatal ASM exposure increases the risk of NDDs in children.
Odile Sheehy +13 more
wiley +1 more source
Diabetes Epidemiology and ManagementStructured abstract: Aims: To assess the prevalence and prevalence relative risk (PRR) of Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) among people with intellectual disabilities (ID) compared to the general population using a ...
Karin Engström +2 more
doaj +1 more source
Annals of Neurology, EarlyView.Objective Immunothrombosis contributes to ischemic stroke pathophysiology through neutrophil extracellular trap (NET) formation, which promotes thrombus stabilization and microvascular dysfunction. DNase1 is the principal endonuclease responsible for NET degradation.
B. Díaz‐Benito +10 more
wiley +1 more source
Annals of Neurology, EarlyView.Objective The optimal treatment for distal medium vessel occlusion (DMVO) stroke remains uncertain, and evidence comparing endovascular therapy (EVT) with medical management (MM) is limited. We aimed to develop and validate a predictive modeling tool to assess individual treatment benefit in DMVO stroke using explainable counterfactual treatment ...
Mohamed F. Doheim +14 more
wiley +1 more source
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source